Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 34517 re-exposure safety study in psychotic major depression
2004-002156-34Phase 2Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of ORG-34517 in Delusional Depression (DD) (2 arms), sponsored by Organon & Co. Primary endpoint: Safety and tolerability of re-exposure to 2 weeks of adjunctive therapy with Org 34517. Started Jan 2006; status: completed.
02
Drugs
ORG-34517
03
Conditions
Delusional Depression (DD)
Beyond the preview
Go deeper on 2004-002156-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002156-34.